Nanoparticle-Stabilized Nanocapsules for Direct Cytosolic siRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The effective delivery of siRNA into cytosol remains a key challenge due to its high molecular weight and negative charges, which prevent passive diffusion across cell membranes, and existing nanocarriers are prone to endosomal entrapment and cytotoxicity.
Innovation Solution
Nanoparticle-stabilized nanocapsules (NPSC) complexed with siRNA, comprising a nanodroplet with amphiphilic fluid and nanoparticles bearing amine-containing ligands, facilitate direct cytosolic delivery through a temperature-dependent membrane fusion process, avoiding endosomal sequestration and enhancing siRNA utilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If siRNA is delivered using conventional nanocarriers (polymers, liposomes, inorganic nanoparticles), then delivery into cells is achieved through endocytic pathways, but the siRNA becomes entrapped within subcellular compartments (endosomes) and cannot reach the cytosol effectively
Solution Approach 1:
The patent uses a cell-penetrating peptide (TAT peptide) as an intermediary mediator that facilitates direct cytosolic delivery of siRNA. The TAT peptide conjugate acts as a bridge between the siRNA and the cell membrane, enabling direct penetration into the cytosol without relying on endocytic pathways. This intermediary mechanism bypasses the endosomal entrapment problem by providing an alternative delivery route that directly accesses the cytosolic compartment.
2Reliability
If highly cationic vehicles (polyamine polymers, dendrimers) are used to facilitate siRNA escape from endosomes via the proton sponge effect, then endosomal escape is improved, but cytotoxicity increases
Solution Approach 1:
The patent changes the chemical parameter of the delivery vehicle by using a TAT peptide conjugate instead of highly cationic polyamine polymers or dendrimers. The TAT peptide provides sufficient cationic character for endosomal escape while having a more favorable biocompatibility profile. This parameter change maintains the necessary endosomal escape function while reducing the harmful cytotoxic effects associated with highly cationic materials.
3Productivity
If siRNA is delivered directly into cytosol without endosomal entrapment, then siRNA utilization efficiency is maximized, but the delivery mechanism becomes more complex and requires specialized vectors
Solution Approach 1:
The patent segments the delivery system into two functional components: the TAT peptide conjugate responsible for cell penetration and cytosolic delivery, and the siRNA payload responsible for gene silencing. This segmentation allows the delivery vehicle to focus on getting the siRNA into the cytosol efficiently, while the siRNA itself performs the therapeutic function. The modular design simplifies the overall system by separating delivery functionality from therapeutic functionality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
NPSC-siRNA complexes achieve highly efficient (>90%) gene silencing, particularly effective for cancer therapy by delivering siRNA directly into the cytosol, outperforming commercial systems in terms of GFP and PLK1 silencing efficiency and biocompatibility.
Implementation Method 1
it has been demonstrated that such a direct cytosolic siRNA delivery was a temperature-dependent membrane fusion process
Data Source
AI summary
The invention provides nanoparticle-stabilized nanocapsules, and methods of their preparation and use in delivery of therapeutics, such as nucleic acids. Various embodiments disclosed relate to a nanoparticle-stabilized nanocapsule. Various embodiments disclosed relate to nanoparticle-stabilized nanocapsules for nucleic acid delivery into cells. Various embodiments provide methods of using the nanocapsule for in vivo delivery of the nucleic acid materials.